Lupin Share price

Q: How to buy Lupin Share at Choice?

To buy Lupin stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Lupin, choose your preferred order type, and place the trade.

LUPIN

Healthcare Large Cap

214345.40 (-2.07%)

NSE

BSE

Last updated on 1 Sep, 2026 | 15:22 IST

BuySell

Today's High

2190.20

Today's Low

2137.60

52 Week Low

1875.00

52 Week High

2529.50

Free Demat with Zero AMC*

Summary

As of 1 Sep, 2026, Lupin stock price is ₹2143. During the trading session, the stock has moved between an intraday low of ₹2137.60 and an intraday high of ₹2190.20. Over the last 52 weeks, Lupin has traded between ₹1875.00 and ₹2529.50.

The stock has recorded a trading volume of 22,822 shares, with a market capitalization of ₹457232536. Its Average Traded Price (ATP) is ₹2146.55, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 2 @ ₹2143.00.

Lupin has an upper circuit limit of ₹2407.20 and a lower circuit limit of ₹1969.60. The total value traded stands at ₹4.90 CR, and the delivery percentage for the day is 79.8%.

The stock is currently traded with a market lot size of 1. Lupin also offers a dividend yield of 0.83%.

Lupin share price chart

ChartIQ

TradingView

Lupin Share Key Metrics

Volume

22822.00

Market Cap

100060.77 CR

LTQ@LTP

2@2143.00

ATP

2146.55

Var Margin

12.5 %

Circuit Range

1969.6-2407.2

Delivery %

79.8 %

Value

4.90 CR

ASM/GSM

No

Market Lot

1

Lupin Fundamentals

P/E Ratio

18.01

P/B Ratio

4.18

Div. Yield

0.83

Sector P/E

41.23

Sector P/B

3.52

Sec. Div. Yield

0.51

Lupin Resistance and Support

Pivot 2175.13

Resistance

First Resistance

2205.26

Second Resistance

2222.13

Third Resistance

2252.26

Support

First Support

2158.26

Second Support

2128.13

Third Support

2111.26

Lupin Futures & Options

Lupin Ltd Share Price

2143

-45.4 (-2.07%)

Lupin Option Chain

View Price, OI, Greeks & More...

View All

29SEP26

2160.80

-9.50 (0.44%)

27OCT26

2171.30

-4.70 (0.22%)

23NOV26

2180.00

-9.10 (0.42%)

LUPIN|29SEP26 CE 2140.00

58.65 -1.95 (-3.22%)

LUPIN|29SEP26 PE 2160.00

46.6 2.75 (6.27%)

Lupin Shareholding Pattern

2016-17
2018-19
2019-20
2020-21
2021-22
2022-23
2023-24
2024-25
2025-26
2026-27

Segment

Percent

Total Promoters

46.85%

Mutual Fund

14.84%

Insurance

6.93%

Foreign Institutional Investors

22.42%

Domestic Institutional Investors

2.88%

Retail

6.08%

Others

Total Promoters

MAR '26

46.86%

JUN '26

46.85%

Lupin Historical Data

Day	Open	Close	Change(%)	Day High	Day Low
Tue Sep 01 2026	2190.2	2143	-2.07%	2190.2	2137.6
Mon Aug 31 2026	2171.5	2188.39	0.78%	2192	2145
Fri Aug 28 2026	2164.89	2171.5	0.62%	2179.8	2153

Lupin Corporate Actions

Date	Agenda
2026-08-06	Quarterly Results
2026-05-07	Audited Results & Final Dividend
2026-02-12	Quarterly Results
2025-11-06	Quarterly Results & Others
2025-08-05	Quarterly Results & Others
2025-05-14	Audited Results & Final Dividend
2025-02-11	Quarterly Results & Others
2024-11-07	Quarterly Results
2024-08-06	Quarterly Results

Ex Date	Record Date
2026-07-17	2026-07-17	View More

Lupin News

Lupin Ltd - 500257 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015- ESG Rating

Lupin has been assigned an independent Environmental, Social, and Governance (ESG) Rating of 'Crisil ESG 69' and a Core ESG Rating of 'Crisil Core ESG 65' for FY26 by Crisil ESG Ratings & Analytics Ltd. The company is placed in the 'Strong' category based on this assessment.

Aug 28 2026 09:41:53

Lupin Ltd - 500257 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

Lupin has been assigned an Environmental, Social and Governance (ESG) rating of '60' by ESG Risk Assessments & Insights Limited. The company is placed in the 'Adequate' category, with the rating being independently prepared from public domain data.

Aug 24 2026 18:53:17

Lupin Ltd - 500257 - Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.

Lupin's subsidiary, VISUfarma B.V., entered an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI™ (an ophthalmic product) in key European markets. This strengthens Lupin's ophthalmology portfolio and expands its presence.

Aug 20 2026 10:54:53

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Demise

Lupin Limited announced the demise of Dr. Sofia Mumtaz, President of Legal & Compliance for Canada, ANZ, and NEA Business, on August 17, 2026. Her role covered significant international operations.

Aug 18 2026 22:10:34

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Lupin received final approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Pitolisant Tablets. This approval covers 4.45 mg and 17.8 mg strengths, and the product is bioequivalent to Wakix®, expanding Lupin's product offering in the US market.

Aug 17 2026 12:21:21

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Lupin Limited will participate in five analyst and institutional investor meetings scheduled from August 13 to September 1, 2026. These meetings are in-person group sessions.

Aug 10 2026 16:19:59

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Lupin announced that the audio recording of the earnings call for Q1 FY27 Results, conducted on August 07, 2026, is available on its website for investor access.

Aug 07 2026 21:30:22

Lupin Ltd - 500257 - Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

Lupin's Board approved Q1 FY27 consolidated financial results. Revenue from operations increased to ₹8,276.89 crores, up 31.06% YoY, while net profit grew 15.96% YoY to ₹1,416.98 crores. The company completed the acquisition of VISUfarma B.V. for ₹2,090.27 crores during the quarter.

Aug 06 2026 21:56:30

Name	Position
Manju D Gupta	Chairperson
Nilesh Gupta	Managing Director

Lupin Similar Stocks

Zydus Lifesciences Ltd.

1162.00

0.70 (0.06%)

Cipla Ltd.

1417.00

7.80 (0.55%)

Lenskart Solutions Ltd.

663.75

1.35 (0.20%)

Laurus Labs Ltd.

1857.00

-58.00 (3.03%)

Manipal Health Enterprises Ltd.

746.35

-16.45 (2.16%)

Mankind Pharma Ltd.

2361.00

-58.20 (2.41%)

Max Healthcare Institute Ltd.

1003.00

-39.10 (3.75%)

Dr. Reddy's Laboratories Ltd.

1170.00

15.60 (1.35%)

Aurobindo Pharma Ltd.

1678.60

-38.40 (2.24%)

Glenmark Pharmaceuticals Ltd.

2455.00

-25.00 (1.01%)

Lupin FAQs

The Buying Price of Lupin share is 2143 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Lupin stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Lupin, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Lupin shares is 18.01. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Lupin shares is 4.18. Useful to assess the stock's value relative to its book value.

To assess Lupin’s valuation compare Sector P/E, P/B which are 41.23 & 3.52 with sector averages, along with growth rates and financial metrics.

The Market Cap of Lupin is 100060.77 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Lupin share price is 2529.50 & 1875.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Lupin belongs to the Healthcare sector.

Open Your Free
Demat Account Now!

AMC for First Year
Auto Square Off Charges

13 Lakh+ Clients
Expert-Backed
Premium Tools